Taro Shibuki, Taiga Otsuka, Mototsugu Shimokawa, Junichi Nakazawa, Shiho Arima, Masaru Fukahori, Keisuke Miwa, Yoshinobu Okabe, Futa Koga, Yujiro Ueda, et al. Nanoliposomal irinotecan with fluorouracil and folinic acid, FOLFIRINOX, and S-1 as second-line treatment for unresectable pancreatic cancer after gemcitabine/nab-paclitaxel. Scientific reports. 2024. 14. 1. 16906-16906
Masayuki Takeda, Mototsugu Shimokawa, Atsushi Nakamura, Kaname Nosaki, Yasutaka Watanabe, Terufumi Kato, Daisuke Hayakawa, Hiroshi Tanaka, Toshiaki Takahashi, Masahide Oki, et al. Corrigendum to "A phase II study (WJOG12819L) to assess the efficacy of osimertinib in patients with EGFR mutation-positive NSCLC in whom systemic disease (T790M-negative) progressed after treatment with first- or second-generation EGFR TKI and platinum-based chemotherapy" [Lung Cancer 177 (2023) 44-50]. Lung cancer (Amsterdam, Netherlands). 2024. 193. 107852-107852
Kaname Nosaki, Kiyotaka Yoh, Ryo Toyozawa, Hidehito Horinouchi, Masahiro Morise, Kadoaki Ohashi, Haruyasu Murakami, Miyako Satouchi, Jun Sakakibara-Konishi, Seiji Yano, et al. Phase 2 trial of crizotinib in Japanese patients with advanced NSCLC harboring a MET gene alteration: a Co-MET study. International journal of clinical oncology. 2024
Shingo Noura, Ryo Inada, Hitoshi Ojima, Takeshi Nagasaka, Hiroaki Tanioka, Yoshinori Munemoto, Yasuhiro Shimada, Keiichiro Ishibashi, Yoshiaki Shindo, Mototsugu Shimokawa, et al. QoL analysis: A randomized phase 3 study of sequential versus combination treatment in firstline chemotherapy for metastatic colorectal cancer-The C-cubed study. JOURNAL OF CLINICAL ONCOLOGY. 2022. 40. 4
Meiko Nishimura, Takahiro Kogawa, Yuko Akaishi, Misato Ogata, Jun Masuda, Mitsuo Terada, Hitomi Sakai, Kazuki Nozawa, Sasagu Kurozumi, Takamichi Yokoe, et al. Clinical evaluation of the efficacy and liquid molecular analysis of abemaciclib rechallenge upon progression to abemaciclib combination therapies for ER-positive HER2-negative metastatic breast cancer patients. CANCER RESEARCH. 2022. 82. 4
橋本幸輝, 林稔展, 下川元継, 松井礼子, 藤堂真紀, 玉木慎也, 原田知彦, 佐野元彦, 小池恭正, 藤田行代志, et al. Multicenter survey analyzing the use of olanzapine for breakthrough chemotherapy-induced nausea and vomiting. 日本臨床腫瘍学会学術集会(CD-ROM). 2022. 19th
Kazuki Takada, Shinkichi Takamori, Naoko Miura, Yasunori Shikada, Mototsugu Shimokawa. Reasons to Consider the COVID-19 Vaccination Status of Patients With Cancer When Analyzing Their COVID-19 Outcomes. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2021. 39. 35. 3996-3996
American Society of Clinical Oncology
, European Society for Medical Oncology
, International Biometric Society
, 日本計量生物学会
, 日本臨床腫瘍学会
, 日本臨床試験学会
, 日本がんサポーティブケア学会